1. |
Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet, 2017, 390(10091): 298-310.
|
2. |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
|
3. |
Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791.
|
4. |
Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol, 2019, 12(1): 115.
|
5. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
6. |
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
|
7. |
屈彦, 王天一, 杨津, 等. GBD数据库的数据提取方法与流程. 中国循证心血管医学杂志, 2019, 11(9): 1043-1046.
|
8. |
李茜瑶, 周莹, 黄辉, 等. 疾病负担研究进展. 中国公共卫生, 2018, 34(5): 777-780.
|
9. |
李辉章, 杜灵彬. Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用. 中华预防医学杂志, 2020, 54(8): 908-912.
|
10. |
Chen HS, Zeichner S, Anderson RN, et al. The Joinpoint-jump and Joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics. J Off Stat, 2020, 36(1): 49-62.
|
11. |
胡成如, 王丽, 孙茜, 等. 体重指数与恶性淋巴瘤关系病例对照研究的Meta分析. 中国循证医学杂志, 2012, 12(1): 55-60.
|
12. |
't Mannetje A, De Roos AJ, Boffetta P, et al. Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Environ Health Perspect, 2016, 124(4): 396-405.
|
13. |
Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014, 2014(48): 130-144.
|
14. |
杜鹏, 李龙. 新时代中国人口老龄化长期趋势预测. 中国人民大学学报, 2021, 35(1): 96-109.
|
15. |
修冰, 刘辉, 李玉兰, 等. CAR-T治疗B细胞淋巴瘤研究新进展. 临床内科杂志, 2022, 39(9): 586-589.
|
16. |
Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol, 2022, 23(2): 155-170.
|
17. |
Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet, 2019, 394(10204): 1192-1204.
|
18. |
Yu H. Universal health insurance coverage for 1.3 billion people:what accounts for China's success? Health Policy, 2015, 119(9): 1145-1152.
|
19. |
Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990—2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY), 2022, 14(7): 3175-3190.
|
20. |
Cai W, Zeng Q, Zhang X, et al. Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990—2019: results from the Global Burden of Disease Study 2019. Front Med (Lausanne), 2021, 8: 738693.
|
21. |
Pfreundschuh M. Age and sex in non-Hodgkin lymphoma therapy: it's not all created equal, or is it. Am Soc Clin Oncol Educ Book, 2017, 37: 505-511.
|
22. |
Crozier JA, Sher T, Yang D, et al. Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review. Clin Lymphoma Myeloma Leuk, 2015, 15(10): 578-585.
|
23. |
郑湧智, 陈再生, 华雪玲, 等. 儿童不同病理亚型非霍奇金淋巴瘤的临床特征及预后因素. 中国实验血液学杂志, 2020, 28(2): 500-506.
|
24. |
Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 589-597.
|
25. |
Howlader N, Morton LM, Feuer EJ, et al. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 174-179.
|
26. |
中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版). 中华肿瘤杂志, 2021, 43(7): 707-735.
|